Qian X, et al. - Experts resolved to gauge the effects of pioglitazone (PIO) on insulin resistance and first phase insulin secretion among obese and lean Chinese people with type 2 diabetes mellitus (T2DM). PIO caused a notable rise in the insulin sensitivity and β-cell function in the lean group as well as in the obese group through 16-week treatment among Chinese T2DM patients. This data illustrated that both lean and obese diabetic adults would profit from PIO.